Last reviewed · How we verify
Graceptor®
Selective estrogen receptor modulator
Selective estrogen receptor modulator Used for Treatment of breast cancer.
At a glance
| Generic name | Graceptor® |
|---|---|
| Also known as | tacrolimus, FK506 |
| Sponsor | Astellas Pharma Inc |
| Drug class | Selective estrogen receptor modulator |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Graceptor acts by selectively modulating the estrogen receptor, which is involved in the regulation of various physiological processes.
Approved indications
- Treatment of breast cancer
Common side effects
- Hot flashes
- Vaginal discharge
Key clinical trials
- Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® (PHASE2)
- A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time (PHASE2)
- Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Graceptor® CI brief — competitive landscape report
- Graceptor® updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI